Reduction in viral load and S&S scores
ADENOVIRUS, VIRUS, COINFECTION, RHINOVIRUS, DISEASE, REMISSION
In Part 1, reductions in viral load at 24 h after a single dose AK0529 administration were <1 log(A) Median change in viral load from baseline to 96 h post‐dose in Part 2 (full analysis population). (B) Median change in Wang respiratory score by dose level in Part 2 (full analysis population). *In Part 1, median Wang Respiratory Score decreased from baseline to 24 h in a dose‐related manner (see plot in the (A) Relationships between viral load and Wang respiratory score: viral load vs. RSV S&S score, In a post‐hoc analysis, 8/11 patients (73%) receiving AK0529 2 mg/kg bid achieved disease remission by Day 5, as defined by Wang Respiratory Score ≤1. In contrast, only 5 out of 16 (31%) in the placebo group (one‐sided Sanger sequencing on Coinfection with ≥1 other respiratory virus was identified in 9/22 analyzed patients in Part 1 (40.9%), including three (13.6%) with ≥2 additional respiratory viruses. In Part 2, ≥1 other respiratory viruses were identified in 13 of 41 analyzed patients, including ≥2 additional respiratory viruses in three patients (7.3%). Human rhinovirus was the most frequently co‐detected virus in both populations, followed by adenovirus C and adenovirus B/E.